Truist Securities reiterates Buy rating on Chemours stock amid operational challenges

Published 07/08/2025, 15:10
Truist Securities reiterates Buy rating on Chemours stock amid operational challenges

Investing.com - Truist Securities maintained its Buy rating and $18.00 price target on Chemours (NYSE:CC) following the company’s second-quarter earnings report. The stock, currently trading at $12.24, has experienced a significant 32.65% decline over the past six months, according to InvestingPro data.

The chemical company’s third-quarter and full-year EBITDA guidance came in below Street expectations, primarily due to operational headwinds in its Titanium Technologies (TT) and Advanced Performance Materials (APM) segments. The company’s current EBITDA stands at $376 million, with a market capitalization of $1.84 billion.

Despite these challenges, Truist noted that Chemours is experiencing stronger-than-expected performance in its Thermal & Specialized Solutions (TSS) segment, driven by continued adoption of its Opteon products.

The research firm characterized the operational issues affecting the TT and APM segments as "short-term in nature" and highlighted the recently announced New Jersey settlement as providing "incremental clarity on the blueprint for resolving legacy PFAS liabilities."

Truist expects Chemours to achieve "significant earnings growth" in 2026 as TSS growth continues and turnaround efforts improve performance in the company’s more cyclical businesses, particularly Titanium Technologies.

In other recent news, Chemours Co reported its financial results for the second quarter of 2025, exceeding analyst expectations. The company achieved an earnings per share (EPS) of $0.58, which was notably higher than the projected $0.46. This represents a 26.09% surprise in EPS. Additionally, Chemours reported revenue of $1.62 billion, surpassing the anticipated $1.56 billion. These results highlight the company’s strong performance during the quarter. There were no reports of mergers or acquisitions involving Chemours. Analyst ratings and other company news were not mentioned in the recent updates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.